IceCure Medical Ltd (NASDAQ:ICCM) Sees Large Decline in Short Interest

IceCure Medical Ltd (NASDAQ:ICCM) saw a large drop in short interest in January. As of January 31st, there was short interest totalling 802,800 shares, a drop of 9.2% from the January 15th total of 883,900 shares. Currently, 3.3% of the shares of the stock are short sold. Based on an average daily volume of 607,200 shares, the short-interest ratio is presently 1.3 days.

Institutional Trading of IceCure Medical

A hedge fund recently raised its stake in IceCure Medical stock. XTX Topco Ltd increased its stake in IceCure Medical Ltd (NASDAQ:ICCM) by 123.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,866 shares of the company’s stock after acquiring an additional 32,555 shares during the quarter. XTX Topco Ltd owned 0.11% of IceCure Medical worth $65,000 at the end of the most recent reporting period. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Trading Down 0.7 %

IceCure Medical stock traded down $0.01 during mid-day trading on Monday, hitting $1.36. 129,205 shares of the stock were exchanged, compared to its average volume of 266,816. The company has a quick ratio of 2.27, a current ratio of 2.67 and a debt-to-equity ratio of 0.02. IceCure Medical has a 12 month low of $0.48 and a 12 month high of $1.45. The firm’s fifty day simple moving average is $1.19 and its two-hundred day simple moving average is $0.84. The stock has a market capitalization of $75.48 million, a price-to-earnings ratio of -4.69 and a beta of 0.40.

IceCure Medical (NASDAQ:ICCM) last released its quarterly earnings results on Tuesday, November 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. Analysts forecast that IceCure Medical will post -0.28 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on ICCM shares. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and issued a $2.50 price objective on shares of IceCure Medical in a report on Wednesday, November 27th.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.